alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT (23)


                  INDEPENDENT AUDITOR'S CONSENT



We hereby consent to the incorporation by reference in the Registration
Statements on Form S-8 (Nos. 33-77516, 33-77518 and 333-2702) pertaining to the
LaCrosse Footwear, Inc. Employees' Retirement Savings Plan, the LaCrosse
Footwear, Inc. Union Employees' Retirement Savings Plan and the LaCrosse
Footwear, Inc. 1993 Employee Stock Incentive Plan of our reports dated February
7, 2003, except for the last paragraph of Note 4, as to which the date is
February 11, 2003, with respect to the consolidated financial statements and the
financial statement schedule included in this Annual Report on Form 10-K of
LaCrosse Footwear, Inc. for the year ended December 31, 2002.

                                        /s/ McGLADREY & PULLEN, LLP
                                        ----------------------------------------
                                        McGLADREY & PULLEN, LLP



Minneapolis, Minnesota
March 27, 2003
# In the United States Court of Federal Claims

OFFICE OF SPECIAL MASTERS

No. 16-1326V Filed: May 1, 2017

UNPUBLISHED

* * * * * * * * * * * * * * * * * * * * * * * * * * * * MAY RUBY JOHNSON, *

* Petitioner, * Ruling on Entitlement; Concession; v. * Influenza (“ Flu”); Shoulder Injury

* Related to Vaccine Administration SECRETARY OF HEALTH * (“SIRVA”); AND HUMAN SERVICES, * Special Processing Unit (“SPU”)

* Respondent. *

*

* * * * * * * * * * * * * * * * * * * * * * * * * * * * Maximillian Muller, Muller Brazil, LLP, Dresher, PA, for petitioner. Claudia Gangi, U.S. Department of Just ice, Washington, DC, for respondent.

RULING ON ENTITLEMENT 1

Dorsey , Chief Special Master:

On October 12, 2016, petit ioner filed a petition fo r compensation under the National Vaccine Injury Compensat ion Program, 42 U.S.C. §300aa-10, et seq.

, 2 (the “Vaccine Act”). Petitioner alleges that she received an influenza (“flu”) vaccine on October 29, 2015, and subsequently suffered a shoulder injury related to vaccine administration (“SIRVA”). Petition at 1. The case was assigned to the Special Processing Unit of the Offi ce of Special Masters.

On April 28, 2017, respondent filed his Ru le 4(c) report in which he concedes that petitioner is entitled to compensation in this case. Respondent’s Rule 4(c) Report

at 1. Specifically, respondent concluded that petit ioner’s alleged injury is consistent with a SIRVA, and that it was caused in fact by the flu vaccine she received on October 29,

2015. Id. at 3. Respondent further agrees t hat petitioner has met the statutory requirements for entitlem ent to compensation. Id.

1 Because this unpublished ruling contains a reaso ned explanation for the action in this case, the undersigned intends to post it on the United States Cour t of Federal Claims' website, in accordance with

the E-Government Act of 2002. 44 U.S.C. § 3501 note (2012) (Federal Management and Promotion of Electronic Government Services). In accordance with Vaccine Rule 18(b), petitioner has 14 days to identify and move to redact medical or other inform ation, the disclosure of which would constitute an unwarranted invasion of privacy. If, upon review, t he undersigned agrees that the identified material fits within this definition, the undersigned will redact such material from public access.

2 National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755. Hereinafter, for ease of citation, all “§” references to the Vaccine Ac t will be to the pertinent subparagraph of 42 U.S.C. § 300aa (2012).2 In view of respondent’s concession and the evidence before me, the undersigned finds that petitioner is entitled to compensation.

IT IS SO ORDERED.

s/Nora Beth Dorsey Nora Beth Dorsey Chief Special Master
EXHIBIT 32.2



CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report of September 30, 2008 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:



(1)       The report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



(2)       The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.







|                          |                                                                     
|------------------------- | --------------------------------------------------------------------
|Dated:  November 12, 2008 | By:  /s/ Ralph M. AmatoRALPH M. AMATO
       Chief Financial Officer
----

(2004/C 33 E/238)

WRITTEN QUESTION E-2192/03

by Paulo Casaca (PSE) to the Commission

(2 July 2003)

Subject:   Testing methods for dairy products

Could the Commission supply an updated list of the Community legislation in force relating to testing methods and inspection techniques used for milk and dairy products, with particular reference to methods for detecting micro-organisms?

Answer given by Mr Byrne on behalf of the Commission

(4 August 2003)

Analyses and tests normally carried out on milk and milk products aim at controlling, on the one hand, their safety and on the other hand, their quality and composition.

With regard to the safety of milk and milk products, the relevant requirements currently in force are those laid down in Council Directive 92/46/EEC of 16 June 1992 laying down the health rules for the production and placing on the market of raw milk, heat-treated milk and milk-based products (1). Certain reference methods used to test against the different criteria set out in the above Directive are laid down in Commission Decision 91/180/EEC of 14 February 1991 laying down certain methods of analysis and testing of raw milk and heat-treated milk (2). However, some of the methods have been subject to adaptations or replaced by new techniques, since they were prescribed in this Decision, in accordance with the recommendations of the Community Reference Laboratory (CRL) for the analysis and testing of milk and milk products. It is indeed one of the duties of this laboratory to provide national reference laboratories (NRLs) with details and updating of analytical methods, to co-ordinate research into new analytical methods and to inform NRLs of advances in this field. The Commission together with the CRL is currently preparing an amendment to Decision 91/180/EEC to be proposed in the near future for approval by the Member States. This will be based on the latest list of reference methods recommended by the CRL. This list will be sent direct to the Honourable Member and to Parliament's Secretariat for information.

In addition, food business operators may use, in routine testing, alternative analytical methods when these methods provide equivalent guarantees and have been validated against the reference methods set above. These alternative methods are not subject to official listing in Community legislation.

----

(1)OJ L 268, 14.9.1992.

(2)OJ L 93, 13.4.1991.

----
Exhibit 32





BIOCORAL, INC.


CERTIFICATION PURSUANT TO


18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO SECTION 906


OF THE SARBANES-OXLEY ACT OF 2002





In connection with the Annual Report of Biocoral, Inc. (the "Company") on Form 10-K for the period ending December 31, 2009, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Nasser Nassiri, the President, CEO, Chairman of the Board of the Company and the Principal Accounting Officer, hereby certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: (1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.





/s/ Nasser NassiriNasser NassiriPresident, CEO, Chairman of the Boardand Principal Accounting Officer








Date: March 30, 2010
**Exhibit 99.27****CONSENT OF V. SPRING**     I, Velasquez Spring, P.Eng., Senior Geologist of Watts, Griffis and McOuat Limited herebyconsent to the use of my name in connection with the following document, which is being filed as anexhibit to and incorporated by reference into the registration statement on Form 40-F of GoldcorpInc. (the “Company”) being filed with the United States Securities and Exchange Commission: 1. The annual information form of the Company dated March 25, 2008, which includesreference to my name in connection with information relating to the San Dimas Mines,and the properties described therein.Date: March 25, 2008         /s/ Velasquez Spring   Name:  Velasquez Spring, P.Eng.   Title:  Senior Geologist
The Honorable Jack Zouhary, U.S. District Judge for the Northern District of Ohio, sitting by designation.

*

NOT RECOMMENDED FOR FULL-TEXT PUBLICATION

File Name: 08a0533n.06

Filed: August 28, 2008

Case No. 07-4465

UNITED STATES COURT OF APPEALS

FOR THE SIXTH CIRCUIT

CARETOLIVE,

Plaintiff-Appellant,

v.

ANDREW VON ESCHENBACH,

Commissioner, Food and Drug

Administration, et al.,

Defendants-Appellees.

_______________________________________

)

)

)

)

)

)

)

)

)

)

)

)

)

ON APPEAL FROM THE

UNITED STATES DISTRICT

COURT FOR THE SOUTHERN

DISTRICT OF OHIO

BEFORE: BATCHELDER and GILMAN, Circuit Judges; ZOUHARY , District Judge. *

ALICE M. BATCHELDER, Circuit Judge. Plaintiff–Appellant CareToLive (“CTL”),

appeals the judgment of the district court dismissing CTL’s action for lack of subject matter

jurisdiction. CTL, which characterizes itself as an association of cancer patients, patient families,

doctors, investors, and advocates, filed suit in the district court to challenge the Food and Drug

Administration’s (“FDA”) decision not to immediately approve a Biologics License Application

(“BLA”) for the vaccine Provenge. The FDA neither approved nor denied the application, but

instead issued a Complete Response Letter to the vaccine’s sponsor, Dendreon Corp., requesting

more information. CTL’s lawsuit named as defendants the Commissioner of the FDA, Andrew von

Eschenbach, M.D., and the Secretary of the United States Department of Health and Human
2

Services, Michael Leavitt, in their official capacities; the complaint also named two FDA officials,

Richard Pazdur, M.D., and Howard Scher, M.D., in both their official and individual capacities.

On November 21, 2007, the district court dismissed CTL’s official-capacity claims for lack

of subject matter jurisdiction, citing ripeness, finality, and sovereign immunity. CTL filed an

immediate notice of appeal. On December 4, 2007, the district court dismissed CTL’s individualcapacity claims. CTL filed no notice of appeal from the latter order, and appeals only the dismissal

of its official-capacity claims.

After carefully reviewing the record, the applicable law, the parties’ briefs and counsels’

arguments, we conclude that the district court did not err in its conclusion that it lacked subject

matter jurisdiction because, at the very least, CTL’s action is unripe. As the district court’s opinion

carefully and correctly sets out the law governing the issues raised, and clearly articulates the reasons

underlying its decision, issuance of a full written opinion by this court would serve no useful

purpose. Accordingly, for the reasons stated in the district court’s opinion dismissing CTL’s officialcapacity claims, we AFFIRM.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         Heart, Lung, and Blood Initial Review Group, Heart, Lung, and Blood Program Project Review Committee.                    

*Date:*                         March 17, 2005.                    

*Time:*                         8 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.                    

*Contact Person:*                         Jeffrey H. Hurst, PhD, Review Branch, Division of Extramural Affairs, National Heart, Lung, and Blood Institute/NIH, 6701 Rockledge Drive, RM 7208, Bethesda, MD 20892, (301) 435-0303,                         *hurstj@nhlbi.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: January 25, 2005.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 05-1829  Filed 1-31-05; 8:45 am]

BILLING CODE 4140-01-M
Restricted Stock and Stock Option Plan



 Exhibit 10.9 
 AMENDMENT NO. 1 
 TO THE 

THERMON GROUP HOLDINGS, INC. 
 RESTRICTED STOCK AND STOCK OPTION PLAN 
 This Amendment No. 1 (the
“Amendment”) to the Thermon Group Holdings, Inc. Restricted Stock and Stock Option Plan (the “Plan”) was adopted by the Board of Directors of Thermon Group Holdings, Inc. on October 27, 2010. 

 

	 	1.	General 

 The Plan
is amended, as of the date hereof, by adding, deleting or otherwise modifying the provisions of this Amendment as noted herein. 
  

	 	2.	Limitation on Number of Shares 

 Section 4(a)(i) of the Plan is amended to delete in its entirety and to substitute therefor the following: 
 (i) Limitation on Number of Shares. The maximum aggregate number of Shares which may be issued (including upon exercise or conversion of Options) pursuant to the Plan shall be 14,378. To the extent
that an Option granted ceases to remain outstanding by reason of termination of rights granted thereunder, forfeiture or otherwise, or if a share of Restricted Stock is repurchased by the Parent, the Shares subject to such Option or which are
repurchased shall again become available for award under the Plan. 
  

	 	3.	Ratification 

 As
amended by this Amendment, the Plan is in all respects ratified and confirmed, and as so amended by this Amendment, the Plan shall be read, taken and construed as one and the same instrument.
# CE2004078EN.01078401.xml

| 27.3.2004 | EN | Official Journal of the European Union | CE 78/784 |
| --- | --- | --- | --- |

27.3.2004

EN

Official Journal of the European Union

CE 78/784

---

(2004/C 78 E/0835)

WRITTEN QUESTION E-3168/03

by Michl Ebner (PPE-DE) to the Council

(27 October 2003)

Subject:   Ban on dangerous dog breeds

Subject:

Unfortunately, my previous questions concerning a ban on dangerous dogs have had no effect. It is true that one or two Member States, Italy and Austria for example, have already taken measures against violent and aggressive dogs by making muzzles compulsory in public places, such as bus stops and parks, and introducing training schools for puppies, but these measures do not go far enough. Recently, we have again been confronted with terrible headlines about pitbulls attacking children and adults. It is not enough that individual Member States or regions tackle the behaviour of some breeds of dog. There must be a European directive banning dangerous dog breeds.

How many more people need to be bitten to death or mutilated in the Council's opinion?

How much longer must we wait before action is finally taken at Community level?

Reply

(4 March 2004)

(4 March 2004)

The Council takes note of the problem raised by the Honourable Member in his question, but would point out that it is not able to respond, since the power of initiative lies with the Commission, which to date has not presented proposals to this effect.

---
# Commission Implementing Regulation (EU) No 327/2014Show full title

Commission Implementing Regulation (EU) No 327/2014 of 26 March 2014 entering a name in the register of protected designations            of origin and protected geographical indications [Requeijão da Beira Baixa (PDO)]         

        - Previous
        - Next

U.K.

# Commission Implementing Regulation (EU) No 327/2014                     

# of 26 March 2014

# entering a name in the register of protected designations of origin and protected geographical indications [Requeijão da Beira                        Baixa (PDO)]                     

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EU) No 1151/2012 of the European Parliament and of the Council of 21 November 2012 on quality                           schemes for agricultural products and foodstuffs(1), and in particular Article 52(2) thereof,                        

Whereas:

(1)Pursuant to Article 50(2)(a) of Regulation (EU) No 1151/2012, Portugal's application to register the name ‘Requeijão da Beira                              Baixa’ was published in the *Official Journal of the European Union* (2).

(2)As no statement of opposition under Article 51 of Regulation (EU) No 1151/2012 has been received by the Commission, the name                              ‘Requeijão da Beira Baixa’ should therefore be entered in the register,

HAS ADOPTED THIS REGULATION:

# Article 1U.K.

The name contained in the Annex to this Regulation is hereby entered in the register.

# Article 2U.K.

This Regulation shall enter into force on the twentieth day following that of its publication in the *Official Journal of the European Union*.                  

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 26 March 2014.

*For the Commission*                            

*On behalf of the President,*                            

Dacian Cioloș                            

*Member of the Commission*                            

## ANNEXU.K.

Agricultural products intended for human consumption listed in Annex I to the Treaty:

### Class 1.4. Other products of animal origin (eggs, honey, various dairy products except butter, etc.)U.K.

#### PORTUGALU.K.

Requeijão da Beira Baixa (PDO)

1

OJ L 343, 14.12 2012, p. 1.                           

2

OJ C 312, 26.10.2013, p. 26.
# Commission Implementing Regulation (EU) No 52/2014Show full title

Commission Implementing Regulation (EU) No 52/2014 of 20 January 2014 establishing the standard import values for determining            the entry price of certain fruit and vegetables         

        - Previous
        - Next

U.K.

# Commission Implementing Regulation (EU) No 52/2014                     

# of 20 January 2014

# establishing the standard import values for determining the entry price of certain fruit and vegetables

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Council Regulation (EC) No 1234/2007 of 22 October 2007 establishing a common organisation of agricultural                           markets and on specific provisions for certain agricultural products (Single CMO Regulation)(1),                        

Having regard to Commission Implementing Regulation (EU) No 543/2011 of 7 June 2011 laying down detailed rules for the application                           of Council Regulation (EC) No 1234/2007 in respect of the fruit and vegetables and processed fruit and vegetables sectors(2), and in particular Article 136(1) thereof,                        

Whereas:

(1)Implementing Regulation (EU) No 543/2011 lays down, pursuant to the outcome of the Uruguay Round multilateral trade negotiations,                              the criteria whereby the Commission fixes the standard values for imports from third countries, in respect of the products                              and periods stipulated in Annex XVI, Part A thereto.

(2)The standard import value is calculated each working day, in accordance with Article 136(1) of Implementing Regulation (EU)                              No 543/2011, taking into account variable daily data. Therefore this Regulation should enter into force on the day of its                              publication in the *Official Journal of the European Union*,

HAS ADOPTED THIS REGULATION:

# Article 1U.K.

The standard import values referred to in Article 136 of Implementing Regulation (EU) No 543/2011 are fixed in the Annex to                     this Regulation.                  

# Article 2U.K.

This Regulation shall enter into force on the day of its publication in the *Official Journal of the European Union*.                  

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 20 January 2014.

*For the Commission, On behalf of the President,*                            

Jerzy Plewa                            

*Director-General for Agriculture and Rural Development*                            

## ANNEXU.K.Standard import values for determining the entry price of certain fruit and vegetables

1

OJ L 299, 16.11.2007, p. 1.                           

2

OJ L 157, 15.6.2011, p. 1.